% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Accardo:9565,
      author       = {Accardo, A. and Mansi, R. and Mirisco, A. and Mangiapia, G.
                      and Paduano, L. and Tesauro, D. and Radulescu, A. and
                      Aurilio, M. and Aloj, L. and Arra, C. and Morelli, G.},
      title        = {{P}eptide modified nanocarriers for selective targeting of
                      bombesin receptors},
      journal      = {Molecular BioSystems},
      volume       = {6},
      issn         = {1742-206X},
      address      = {Cambridge},
      publisher    = {Royal Society of Chemistry},
      reportid     = {PreJuSER-9565},
      pages        = {878 - 887},
      year         = {2010},
      note         = {We thank Prof. Helmut Maecke, University Hospital Basel,
                      Switzerland for the helpful discussions and suggestions. We
                      are indebted to EMIL, European Molecular Imaging
                      Laboratories, for financial support. Some of us (LP, GM, AR)
                      wish to thank the Forschungszentrum Julich for provision of
                      beam time.},
      abstract     = {The present work describes new supramolecular aggregates
                      obtained by co-assembling two different amphiphilic
                      molecules, one containing the bioactive bombesin peptide
                      (BN), or a scramble sequence, and the other, the DOTA
                      chelating agent, (C18)(2)DOTA, capable of forming stable
                      complexes with the radioactive (111)In(III) isotope. The
                      peptide in the amphiphilic monomer is spaced by the
                      lipophilic moiety through ethoxylic spacers of different
                      length: a shorter spacer with five units of dioxoethylene
                      moieties in (C18)(2)L5-peptide, or a longer spacer
                      consisting of a Peg3000 residue in (C18)(2)Peg3000-peptide.
                      Structural characterization by SANS and DLS techniques
                      indicates that, independently from the presence of the
                      peptide containing monomer in the final composition, the
                      predominant aggregates are liposomes of similar shape and
                      size with a hydrodynamic radius R(h) around 200 nm and
                      bilayer thickness, d, of 4 nm. In vitro data show specific
                      binding of the (111)In-(C18)(2)DOTA/(C18)(2)L5-[7-14]BN
                      90:10 liposomes in receptor expressing cells. However, the
                      presence of the Peg3000 unit on the external liposomal
                      surface, could hide the peptide and prevent the receptor
                      binding. In vivo experiments using
                      (111)In-(C18)(2)DOTA/(C18)(2)L5-[7-14]BN show the expected
                      biological behavior of aggregates of such size and molecular
                      composition, moreover there is an increase in concentration
                      of the GRPR targeting aggregate in the tumors compared to
                      control at the 48 h time point evaluated $(2.4\%$ ID/g
                      versus $1.6\%$ ID/g).},
      keywords     = {Cell Line, Tumor / Chelating Agents: chemistry /
                      Heterocyclic Compounds, 1-Ring: chemistry / Humans /
                      Liposomes: chemistry / Models, Theoretical / Molecular
                      Structure / Peptides: chemistry / Peptides: metabolism /
                      Receptors, Bombesin: metabolism / Chelating Agents (NLM
                      Chemicals) / Heterocyclic Compounds, 1-Ring (NLM Chemicals)
                      / Liposomes (NLM Chemicals) / Peptides (NLM Chemicals) /
                      Receptors, Bombesin (NLM Chemicals) /
                      1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
                      (NLM Chemicals) / J (WoSType)},
      cin          = {IFF-4 / IFF-5 / Jülich Centre for Neutron Science JCNS
                      (JCNS) ; JCNS},
      ddc          = {540},
      cid          = {I:(DE-Juel1)VDB784 / I:(DE-Juel1)VDB785 /
                      I:(DE-Juel1)JCNS-20121112},
      pnm          = {BioSoft: Makromolekulare Systeme und biologische
                      Informationsverarbeitung / Großgeräte für die Forschung
                      mit Photonen, Neutronen und Ionen (PNI)},
      pid          = {G:(DE-Juel1)FUEK505 / G:(DE-Juel1)FUEK415},
      experiment   = {EXP:(DE-MLZ)KWS2-20140101},
      shelfmark    = {Biochemistry $\&$ Molecular Biology},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:20567774},
      UT           = {WOS:000277315800015},
      doi          = {10.1039/b923147a},
      url          = {https://juser.fz-juelich.de/record/9565},
}